LEADING BIOTECHNOLOGY MERGERS AND ACQUISITIONS FOR THE 10-YEAR PERIOD ENDED DECEMBER 31, 2009 REVEALED BY DEALSEARCHONLINE.COM

Amgen announced its $11.1 billion acquisition of Immunex in 2001 and Amgen announced its $2.65 billion acquisition of Abgenix in 2005. Eli Lilly and Co. announced its $6.5 billion acquisition of ImClone Systems in 2008 and Lilly announced its $2.3 billion acquisition of Icos Corporation in 2006. Genzyme Corporation announced its $2.8 billion acquisition of the Bayer hematologic oncology portfolio in 2009 and Genzyme announced its $1.9 billion acquisition of the worldwide license for mipomersen from Isis Pharmaceuticals in 2008.

Biotechnology Mergers and Acquisitions, 2000 to 2009
Year	Dollars Committed	Number Of Deals
2009	$47,523,349,040	193
2008	$93,879,257,347	148
2007	$42,105,127,700	145
2006	$36,407,170,500	115
2005	$23,196,902,050	113
2004	$6,764,873,000	96
2003	$16,681,231,200	128
2002	$3,274,727,708	96
2001	$20,150,840,000	85
2000	$5,076,797,094	52
Totals	$295,060,275,639	1,171

 

Only about 18% of the biotechnology companies that were targeted in mergers and acquisitions announced during the 10 years ended December 31, 2009 were producing disclosed revenues at the time of the announcements.  Among the top 25 mergers and acquisitions for the same period, 76% of the biotechnology companies targeted were producing revenues at the time the deals were announced.  
 

Most of the top 25 largest biotechnology mergers and acquisitions announced during the 10-year period ended December 31, 2009 targeted a United States-based concern, although seven of the top 25 mergers and acquisitions targeted entities based in Europe. Most of the acquirers in the top 25 biotechnology mergers and acquisitions announced from 2000 to 2009 were also U.S.-based, but also included acquisitions announced by eight companies based in Europe, one in Canada and one in Japan.
 

Geographically, for the 10-year period ended December 31, 2009, the states that were home to the acquirers in the greatest numbers of biotechnology mergers and acquisitions included California, New York, Massachusetts, New Jersey, Maryland, Pennsylvania, North Carolina, Washington and Texas. Outside the U.S., the countries that were home to the acquirers in the greatest numbers of biotechnology mergers and acquisitions included Switzerland, Germany, England, Netherlands, Japan, Canada, France, Australia and Denmark. On the sell-side, for the same 10-year period, the states that were home to the targets in the greatest numbers of biotechnology mergers and acquisitions included California, Massachusetts, Maryland, New York, New Jersey, Washington, Pennsylvania, North Carolina and Texas. Outside the U.S., the countries appearing most frequently as the home base of the target included Canada, England, Switzerland, Germany and France.

Information in this press release is based on data drawn from DealSearchOnline.com, an online publication of Irving Levin Associates, Inc. Online and available 24/7 at www.dealsearchonline.com, DealSearchOnline.com is a database of current and historic health care mergers and acquisitions, with deal summaries on more than 15,000 mergers and acquisitions since 1993 in the following sectors: Behavioral Health Care; Biotechnology; e-Health; Home Health Care; Hospitals; Laboratories, MRI and Dialysis; Long Term Care; Managed Care; Medical Devices; Pharmaceuticals; Physician Medical Groups; Rehabilitation; and Other Health Care Services. Deal summaries include details such as deal terms, target and acquirer contact information (including e-mail addresses), and price to revenue multiples. Searching is free. Visit www.dealsearchonline.com for a login. Data is immediately available for download or to print, with a credit card or the purchase of a subscription. Certain Irving Levin Associates, Inc. print publications include special online access to the database for subscribers. Call 1-800-248-1668 for details on subscription options, or email customerservice@levinassociates.com.